267 related articles for article (PubMed ID: 9384487)
1. Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
Okamoto T; Okada M; Mori A; Saheki K; Takatsuka H; Wada H; Tamura A; Fujimori Y; Takemoto Y; Kanamaru A; Kakishita E
Bone Marrow Transplant; 1997 Nov; 20(9):801-3. PubMed ID: 9384487
[TBL] [Abstract][Full Text] [Related]
2. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
[TBL] [Abstract][Full Text] [Related]
3. [Foscarnet therapy for ganciclovir-refractory cytomegalovirus hepatitis in a patient who underwent bone marrow transplantation from an unrelated donor].
Fujisaki T; Gondo H; Uchida N; Matsuo I; Takenaka K; Tanimoto K; Otsuka T; Minematsu T; Minamishima Y; Niho Y
Rinsho Ketsueki; 1997 Feb; 38(2):142-5. PubMed ID: 9059069
[TBL] [Abstract][Full Text] [Related]
4. CMV retinitis after cessation of ganciclovir therapy for CMV antigenemia in an unrelated BMT recipient.
Suzuki N; Kudoh T; Mizue N; Watanabe J; Ikehata M; Tateno M; Ooguro H; Chiba S
Bone Marrow Transplant; 1998 Nov; 22(9):931-2. PubMed ID: 9827825
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation.
Kaulfersch W; Urban C; Hauer C; Lackner H; Gamillscheg A; Slavc I; Langmann G
Bone Marrow Transplant; 1989 Sep; 4(5):587-9. PubMed ID: 2551437
[TBL] [Abstract][Full Text] [Related]
6. Intraocular therapy for cytomegalovirus retinitis.
Palestine AG
J Int Assoc Physicians AIDS Care; 1996 May; 2(5):25-8. PubMed ID: 11363527
[TBL] [Abstract][Full Text] [Related]
7. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Jabs DA
Infect Agents Dis; 1995 Sep; 4(3):131-42. PubMed ID: 8548191
[TBL] [Abstract][Full Text] [Related]
8. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcomes of cytomegalovirus retinitis after transplantation.
Eid AJ; Bakri SJ; Kijpittayarit S; Razonable RR
Transpl Infect Dis; 2008 Feb; 10(1):13-8. PubMed ID: 17511815
[TBL] [Abstract][Full Text] [Related]
10. Pre-emptive ganciclovir treatment can play a role in restoration of hematopoiesis after allogeneic bone marrow transplantation.
Choi JH; Kim DW; Cho SG; Yoo JH; Jeong DC; Han CW; Shin WS; Min WS; Kim HK; Kim CC; Kim DJ
Bone Marrow Transplant; 1997 Jan; 19(2):187-90. PubMed ID: 9116619
[TBL] [Abstract][Full Text] [Related]
11. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.
Ohta H; Matsuda Y; Tokimasa S; Sawada A; Kim JY; Sashihara J; Amo K; Miyagawa H; Tanaka-Taya K; Yamamoto S; Tano Y; Aono T; Yamanishi K; Okada S; Hara J
Bone Marrow Transplant; 2001 Jun; 27(11):1141-5. PubMed ID: 11551024
[TBL] [Abstract][Full Text] [Related]
12. Ganciclovir implants: one year later.
Cadman J
GMHC Treat Issues; 1997; 11(4/5):3-6. PubMed ID: 11364375
[TBL] [Abstract][Full Text] [Related]
13. Early treatment of CMV antigenemia with ganciclovir for prevention of fatal CMV disease in patients receiving marrow from HLA-matched unrelated donors.
Shimokawa T; Morishima Y; Kitaori K; Kato C; Sao H
Int J Hematol; 1999 Aug; 70(2):119-26. PubMed ID: 10497851
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.
Seo SK; Regan A; Cihlar T; Lin DC; Boulad F; George D; Prasad VK; Kiehn TE; Polsky B
Clin Infect Dis; 2001 Nov; 33(9):e105-8. PubMed ID: 11577375
[TBL] [Abstract][Full Text] [Related]
15. [Ganciclovir-resistant cytomegalovirus infection: 2 cases with different clinical impact].
Reusser P; Hostettler B; Attehbofer R
Schweiz Med Wochenschr; 1996 Oct; 126(42):1779-84. PubMed ID: 8966510
[TBL] [Abstract][Full Text] [Related]
16. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of foscarnet for preemptive therapy against cytomegalovirus reactivation after unrelated cord blood transplantation.
Takami A; Mochizuki K; Ito S; Sugimori C; Yamashita T; Asakura H; Okumura H; Nakao S
Transplant Proc; 2007; 39(1):237-9. PubMed ID: 17275512
[TBL] [Abstract][Full Text] [Related]
18. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
20. New treatment options for CMV retinitis in AIDS.
Lalezari JP
Adv Nurse Pract; 1997 Apr; 5(4):45-9, 83. PubMed ID: 9459896
[No Abstract] [Full Text] [Related]
[Next] [New Search]
